FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
…unmet need. More treatment options are needed for these patients. “This is not the outcome the melanoma community had hoped…
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
…unmet need. More treatment options are needed for these patients. “This is not the outcome the melanoma community had hoped…
,
,
Julie Frampton: Part of the Solution
…M.D. Anderson Cancer Center for the surgery, a second opinion on the pathology report, and a diagnosis. Her melanoma is…
,
,
President’s Letter |September 2020
From the Desk of Samantha Guild The f all is upon us, and here at AIM at Melanoma, we’re busy…
,
Have You Checked Out Our New Website?
…new content has been added. All of those affected by melanoma—whether you are newly diagnosed, currently undergoing treatment for melanoma,…
International Survivor Spotlight: José Correia, Portugal
…after 24 years,” he said. Still, he did think about the need for more information and resources for melanoma prevention…
,
,
From Survivors to Advocates: Two Leaders are Pushing for Progress in Canada and Around the World
…was Kathy Barnard, a Stage IV melanoma survivor and the founder of Save Your Skin Foundation, a Canada-based, patient-led organization…
,
,
ASCO Update 2023
…disease such as melanoma; in other years, less. Was there anything special in melanoma at ASCO 2023? Yes! ASCO is…
,
Melanoma By The State: Nevada
…the Nevada melanoma estimates for 2018 included 790 newly diagnosed melanoma cases and 90 deaths. Nevadans Are Taking Action The…
,
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
…the most efficacy in melanomas and has demonstrated antitumor efficacy and durable CRs in patients with heavily pretreated metastatic melanoma.2…
,
,
IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma
…melanoma.” “These data show the potential of a therapeutic cancer vaccine in patients with metastatic melanoma,” said Jessica Hassel, MD,…
,
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026